KIF5B-RET fusions in lung adenocarcinoma

By T. Kohno, H. Ichikawa, Y. Totoki, K. Yasuda, M. Hiramoto, T. Nammo, H. Sakamoto, K. Tsuta, K. Furuta, Yoko Shimada and 19 more. Nature Medicine, 2012

818 citations recorded by the source corpus.

We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1–2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing. The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.

Subfields: Cancer Research, Cell Biology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/a9ee0523dd6291f5f879c0615519be79378a992d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Cell Biology

Steven A. Carr

In Molecular Biology

Citations in the corpus

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. (2016, neutral): “10 15 (53) 28 (28) 152 (90) Race White, non-Hispanic 28 (100) 79 (80) 157 (93) Asian 0 (0) 15 (15) 0 (0) Black 0 (0) 1 (1) 5 (3) White, Hispanic 0 (0) 3 (3) 3 (2) Unknown 0 (0) 1 (1) 4 (2) Histology Adenocarcinoma 18 (64) 92 (93) 150 (89) Pleomorphic with adenocarcinoma component 4 (14) 0 (0) 3 (2) ”
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (2015, neutral): “Activating RET translocations also occur, but much less frequently, in patients with lung adenocarcinoma and chronic myelomonocytic leukemia (28,29).”
Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma (2020, background): “, 2014), andRET fusions (Gautschi et al., 2017; Kohno et al., 2012; Takeuchi et al., 2012), a substantial proportion of LUADs still lack known or currently targetable mutations.”
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology (2018, background): “RET fusion occurs more frequently in never smokers than ever smokers.(37,62,64,66,72) Patients with RET fusion harboring tumors are usually younger than patients with an EGFR mutation and have an equal gender distribution.”
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “The RET (rearranged during transfection) is a novel fusion gene with various partners including KIF5B (kinesin family member 5B) and others such as CCDC6, NCOA4, and TRIM33 (146).”